Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6

[1]  H. Engelhard,et al.  Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. , 1994, Cancer research.

[2]  K. Danø,et al.  Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin. , 1993, The Biochemical journal.

[3]  J. Wilting,et al.  Recent research on the biological activity of suramin. , 1993, Pharmacological reviews.

[4]  C. Stein,et al.  Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. , 1993, Cancer research.

[5]  K. Danø,et al.  Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. , 1993, The Journal of biological chemistry.

[6]  G. Wilding,et al.  Disruption of mitochondrial function by suramin measured by rhodamine 123 retention and oxygen consumption in intact DU145 prostate carcinoma cells. , 1992, Cancer research.

[7]  R. Motzer,et al.  Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. , 1992, Cancer research.

[8]  W. Linehan,et al.  Suramin interference with transforming growth factor-beta inhibition of human renal cell carcinoma in culture. , 1992, The Journal of surgical research.

[9]  A. Sumiyoshi,et al.  The content of urokinase‐type plasminogen activator antigen as a prognostic factor in urinary bladder cancer , 1992, International journal of cancer.

[10]  S. Chang,et al.  Inhibitory effects of suramin on a human renal cell carcinoma line, causing nephrogenic hepatic dysfunction. , 1992, The Journal of urology.

[11]  C. Taylor,et al.  Effects of suramin on in vitro growth of fresh human tumors. , 1992, Journal of the National Cancer Institute.

[12]  G. Wilding,et al.  Disruption of cellular energy balance by suramin in intact human prostatic carcinoma cells, a likely antiproliferative mechanism. , 1991, Cancer research.

[13]  G. Nicolson,et al.  Suramin. A potent inhibitor of melanoma heparanase and invasion. , 1991, The Journal of biological chemistry.

[14]  R. Danesi,et al.  A pilot study of suramin in the treatment of metastatic renal cell carcinoma , 1991, Cancer.

[15]  E. Kohn,et al.  Suramin inhibits laminin- and thrombospondin-mediated melanoma cell adhesion and migration and binding of these adhesive proteins to sulfatide. , 1990, Cancer research.

[16]  I. Fidler,et al.  In vivo selection of human renal cell carcinoma cells with high metastatic potential in nude mice , 1989, Clinical & Experimental Metastasis.

[17]  E. Ishikawa,et al.  Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder. , 1989, Cancer research.

[18]  S. Kohga,et al.  Comparative study of plasminogen activator antigens in colonic carcinomas and adenomas , 1988, International journal of cancer.

[19]  J. Collins,et al.  Quantification of suramin by reverse-phase ion-pairing high-performance liquid chromatography , 1985 .

[20]  B. Cragg,et al.  Experimental animal model for mucopolysaccharidosis: suramin-induced glycosaminoglycan and sphingolipid accumulation in the rat. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[22]  C. Loveday,et al.  Effects of suramin on complement, blood clotting, fibrinolysis and kinin formation , 1973, British journal of pharmacology.

[23]  M. Mariani,et al.  Inhibition of lung and liver tumor colonies in mice pretreated with suramin. , 1993, Invasion & metastasis.

[24]  A. Sumiyoshi,et al.  Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells. , 1991, Invasion & metastasis.

[25]  丸塚 浩助.  Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cell , 1990 .

[26]  G. Markus.  The relevance of plasminogen activators to neoplastic growth. A review of recent literature. , 1988, Enzyme.

[27]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.